Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects
Sunil Babu, M.D.
, Michael Liu, M.D.
, and Robert G. Lerner, M.D.
Dr. Babu is Fellow in Hematology/Oncology at New York Medical College/Westchester Medical Center, Valhalla, NY, and Dr. Liu is Resident in Internal Medicine at Cabrini Medical Center, New York, NY.
Within the past 12 months, Dr.Babu and Dr. Liu report no commercial conflicts of interest. Dr. Lerner reports research support from Boehringer-Ingelheim, Sanofi-Aventis and Bayer and is on the Speakers Bureau for Sanofi-Aventis, GlaxoSmithKline and Eisai.
Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.
This activity is made possible by an unrestricted educational grant from
Estimated time to complete:
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®
, you should be able to:
- Describe the common side effects associated with EGFR inhibition
- Discuss the correlation between dermatologic side effects of EGFR inhibition and response to therapy
- Discuss the possible mechanisms of dermatologic side effects of EGFR inhibitor therapy
- Discuss the common principles of management of dermatologic and non-dermatologic side effects.